PulseAugur
EN
LIVE 22:17:48
中文(ZH) 2连板海南海药：抗肝纤维化创新药氟非尼酮胶囊已完成II期临床试验，目前Ⅲ期临床研究正按计划推进

Hainan Haiyao's anti-liver fibrosis drug completes Phase II trials

By PulseAugur Editorial · [1 sources] ·

Hainan Haiyao has announced that its innovative anti-liver fibrosis drug, Flufenidone Capsules, has successfully completed Phase II clinical trials. The company is currently proceeding with Phase III clinical research as planned. Additionally, their novel anti-epilepsy drug, Piengabin Tablets, has finished Phase IIa trials and is advancing into Phase IIb trials. AI

RANK_REASON The item reports on the completion of Phase II clinical trials for a novel drug, indicating a research milestone. [lever_c_demoted from research: ic=1 ai=0.1]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Hainan Haiyao's anti-liver fibrosis drug completes Phase II trials

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Hainan Haiyao, with two consecutive daily limits, announces that its innovative anti-liver fibrosis drug, Fenofibrate Capsules, has completed Phase II clinical trials, and the Phase III clinical study is currently progressing as planned.

    36氪获悉，海南海药公告，公司抗肝纤维化创新药氟非尼酮胶囊已完成II期临床试验，目前Ⅲ期临床研究正按计划推进；公司抗癫痫创新药派恩加滨片已完成IIa期临床试验，目前IIb期临床试验正在按计划推进。新药研发具有周期长、投入大、风险高的特点，临床试验过程和结果存在诸多不确定性，后续能否获得批准上市存在不确定性，短期内对公司业绩不会产生重大影响。公司将根据进展情况及时履行信息披露义务，敬请广大投资者注意投资风险。

RELATED ENTITIES

RELATED TOPICS